Make Better Decisions

  • Analyze global market entry opportunities
  • Uncover prior art in expired and abandoned patents
  • Drug patents in 130+ countries
➤ Start Trial

or, See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Teva
McKesson
Harvard Business School
Fuji
Deloitte
QuintilesIMS
Julphar
Queensland Health
Federal Trade Commission
Moodys

Generated: January 20, 2018

DrugPatentWatch Database Preview

Sumatriptan succinate - Generic Drug Details

« Back to Dashboard

What are the generic sources for sumatriptan succinate and what is the scope of sumatriptan succinate freedom to operate?

Sumatriptan succinate
is the generic ingredient in eight branded drugs marketed by Meridian Medcl, Glaxosmithkline, Antares Pharma Inc, Aurobindo Pharma Ltd, Dr Reddys Labs Inc, Fresenius Kabi Usa, Hikma Farmaceutica, Injectalia, Mylan Labs Ltd, Par Pharm, Par Sterile Products, Sagent Agila, Sagent Strides, Sandoz Inc, Sun Pharma Global, Teva Parenteral, Teva Pharms Usa, West-ward Pharms Int, Wockhardt, Endo Ventures Ltd, Avanir Pharms, Dr Reddys Labs Ltd, Teva Branded Pharm, Apotex Inc, Aurobindo Pharma, Hikma Pharms, Mylan, Orchid Hlthcare, Roxane, Sandoz, Sun Pharm Inds, Sun Pharm Inds Ltd, Teva, and Watson Labs, and is included in thirty-nine NDAs. There are thirty-six patents protecting this compound and two Paragraph IV challenges. Additional information is available in the individual branded drug profile pages.

Sumatriptan succinate has four hundred and forty-four patent family members in thirty-seven countries.

There are twenty-four drug master file entries for sumatriptan succinate. Forty-seven suppliers are listed for this compound. There are five tentative approvals for this compound.
Summary for sumatriptan succinate
Tentative approvals for SUMATRIPTAN SUCCINATE
Applicant Application No. Strength Dosage Form
➤ Subscribe➤ SubscribeEQ 25MG BASETABLET;ORAL
➤ Subscribe➤ SubscribeEQ 100MG BASETABLET;ORAL
➤ Subscribe➤ SubscribeEQ 50MG BASETABLET;ORAL

US Patents and Regulatory Information for sumatriptan succinate

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Sandoz SUMATRIPTAN SUCCINATE sumatriptan succinate TABLET;ORAL 076976-002 Aug 10, 2009 DISCN No No ➤ Subscribe ➤ Subscribe ➤ Subscribe
Teva SUMATRIPTAN SUCCINATE sumatriptan succinate TABLET;ORAL 076840-003 Feb 9, 2009 DISCN No No ➤ Subscribe ➤ Subscribe ➤ Subscribe
Endo Ventures Ltd SUMAVEL DOSEPRO sumatriptan succinate INJECTABLE;SUBCUTANEOUS 022239-001 Jul 15, 2009 BX RX Yes Yes ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Hikma Pharms SUMATRIPTAN SUCCINATE sumatriptan succinate TABLET;ORAL 078298-001 May 21, 2013 DISCN No No ➤ Subscribe ➤ Subscribe ➤ Subscribe
Avanir Pharms ONZETRA XSAIL sumatriptan succinate POWDER;INHALATION 206099-001 Jan 27, 2016 RX Yes Yes ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Fresenius Kabi Usa SUMATRIPTAN SUCCINATE sumatriptan succinate INJECTABLE;SUBCUTANEOUS 079240-002 Sep 18, 2009 DISCN No No ➤ Subscribe ➤ Subscribe ➤ Subscribe
Aurobindo Pharma SUMATRIPTAN SUCCINATE sumatriptan succinate TABLET;ORAL 078327-001 Aug 10, 2009 AB RX No No ➤ Subscribe ➤ Subscribe ➤ Subscribe
West-ward Pharms Int SUMATRIPTAN SUCCINATE sumatriptan succinate INJECTABLE;SUBCUTANEOUS 079123-001 Feb 6, 2009 AP RX No No ➤ Subscribe ➤ Subscribe ➤ Subscribe
Teva Branded Pharm ZECUITY sumatriptan succinate SYSTEM;IONTOPHORESIS 202278-001 Jan 17, 2013 DISCN Yes No ➤ Subscribe ➤ Subscribe ➤ Subscribe
Sun Pharma Global SUMATRIPTAN SUCCINATE sumatriptan succinate INJECTABLE;SUBCUTANEOUS 090358-001 Jun 21, 2011 AB RX No No ➤ Subscribe ➤ Subscribe ➤ Subscribe
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Expired US Patents for sumatriptan succinate

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Glaxosmithkline IMITREX sumatriptan succinate TABLET;ORAL 020132-001 Jun 1, 1995 ➤ Subscribe ➤ Subscribe
Glaxosmithkline IMITREX sumatriptan succinate TABLET;ORAL 020132-001 Jun 1, 1995 ➤ Subscribe ➤ Subscribe
Glaxosmithkline IMITREX STATDOSE sumatriptan succinate INJECTABLE;SUBCUTANEOUS 020080-003 Dec 23, 1996 ➤ Subscribe ➤ Subscribe
Endo Ventures Ltd SUMAVEL DOSEPRO sumatriptan succinate INJECTABLE;SUBCUTANEOUS 022239-001 Jul 15, 2009 ➤ Subscribe ➤ Subscribe
Glaxosmithkline IMITREX sumatriptan succinate INJECTABLE;SUBCUTANEOUS 020080-001 Dec 28, 1992 ➤ Subscribe ➤ Subscribe
Glaxosmithkline IMITREX sumatriptan succinate TABLET;ORAL 020132-003 Jun 1, 1995 ➤ Subscribe ➤ Subscribe
Endo Ventures Ltd SUMAVEL DOSEPRO sumatriptan succinate INJECTABLE;SUBCUTANEOUS 022239-001 Jul 15, 2009 ➤ Subscribe ➤ Subscribe
Glaxosmithkline IMITREX sumatriptan succinate TABLET;ORAL 020132-002 Jun 1, 1995 ➤ Subscribe ➤ Subscribe
Glaxosmithkline IMITREX sumatriptan succinate TABLET;ORAL 020132-003 Jun 1, 1995 ➤ Subscribe ➤ Subscribe
Glaxosmithkline IMITREX sumatriptan succinate TABLET;ORAL 020132-001 Jun 1, 1995 ➤ Subscribe ➤ Subscribe
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Non-Orange Book US Patents for sumatriptan succinate

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
8,555,878 Nasal delivery device ➤ Subscribe
9,138,538 Device for readying a needle free injector for delivery ➤ Subscribe
9,205,208 Nasal devices ➤ Subscribe
8,596,278 Nasal devices ➤ Subscribe
7,740,014 Nasal devices ➤ Subscribe
7,543,581 Nasal devices ➤ Subscribe
9,522,243 Nasal devices ➤ Subscribe
9,132,249 Nasal devices ➤ Subscribe
9,468,727 Nasal delivery ➤ Subscribe
7,347,201 Nasal delivery devices ➤ Subscribe
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Patents for sumatriptan succinate

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

US Army
Harvard Business School
Fuji
McKesson
Deloitte
Dow
QuintilesIMS
Moodys
Healthtrust

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot